U.S. markets close in 5 hours 59 minutes

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.87+14.59 (+71.92%)
As of 10:01AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close20.28
Bid34.72 x 1000
Ask35.04 x 800
Day's Range32.13 - 37.26
52 Week Range4.49 - 37.26
Avg. Volume1,088,757
Market Cap4.556B
Beta (5Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-1.85
Earnings DateNov 02, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IMVT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immunovant, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Motley Fool

    These 2 Biotech Stocks Are Bucking a Down Market Tuesday

    For instance, Monday's trading session gave market participants some optimism about how the economy could weather difficult times, but based on Tuesday morning's stock index futures movements, it's just difficult to build lasting positive momentum. Based on current futures levels, stocks looked poised to give back much of Monday's gains at the open on Tuesday morning. Both Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV) are relatively small players in biotech right now, but the latest news on one candidate treatment had investors feeling better about their long-term prospects.

  • GlobeNewswire

    Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

    IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage

  • GlobeNewswire

    Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

    NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. To participate in the conference call, please register in advance here. To access the live a